ABLYNX ANNOUNCES WARRANT EXERCISE
(Thomson Reuters ONE) -
REGULATED INFORMATION
GHENT, Belgium, 9 December 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY]
today announced, in conformity with Title II of the Law of 2 May 2007 and the
Royal Decree of 14 February 2008, that that an additional 7,250 common shares
have been issued by the Company in exchange for ?61,390.00 as the result of the
exercise of warrants by some employees and consultants of the Company.
As a result of this transaction, Ablynx now has 54,524,874 shares outstanding.
The total number of rights (warrants) to subscribe to not yet issued securities
conferring voting rights currently is 2,938,745 which equals the total number of
voting rights that may result from the exercise of these warrants. Currently
1,000 convertible bonds are outstanding entitling the holders thereof to
7,733,952 shares of the Company in the aggregate, upon conversion of such
convertible bonds.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of
Nanobodies(®), proprietary therapeutic proteins based on single-domain antibody
fragments, which combine the advantages of conventional antibody drugs with some
of the features of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the Company has
more than 30 proprietary and partnered programmes in development in various
therapeutic areas including inflammation, haematology, immuno-oncology, oncology
and respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm,
Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho
Pharmaceutical Co., Ltd. The Company is headquartered in Ghent, Belgium. More
information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: ablynx(at)instinctif.com
Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: ablynx(at)instinctif.com
Pdf version of the press release:
http://hugin.info/137912/R/1972053/721206.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via GlobeNewswire
[HUG#1972053]
Unternehmensinformation / Kurzprofil:
Datum: 09.12.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 438455
Anzahl Zeichen: 3438
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 354 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX ANNOUNCES WARRANT EXERCISE"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
